The Liquid Biopsy Research Group

Can #fragmentomics become a new monitoring #biomarker in metastatic breast cancer? 🔬 👉 Here we explore a mutation-agnostic, cost-effective approach tested in the MAGNETIC.1 trial—a longitudinal study of first-line HR+/HER2- MBC. doi.org/10.1016/j.tran…

🏁 Our program on cellular residual disease in triple negative breast cancer is about to launch! Detecting circulating tumor cells in early #TNBC will provide deeper insights into the metastatic process and #immunotherapy response #BreastCancer #LiquidBiopsy #CTC @CroAviano

🔬 Exciting Liquid Biopsy session under the patronage of the International Society of Liquid Biopsy 📍 View the full program and register here: focusontop.it #FocusOnTop #LiquidBiopsy #CTCs #ctDNA #PrecisionOncology #FTOP25 #BreastCancer @isliquidbiopsy

🗓️Mark Your Calendars! Join us at FOCUS on TOP in Udine, Italy, on March 17-18, 2025! 📍 Venue: Hotel Là di Moret, Udine, Italy 🚆 Train: Udine railway station ✈️ Airports: Venice Marco Polo, Trieste - Friuli Venezia Giulia 🌐 More Info: focusontop.it

🎤 Hear it from our speakers! On March 17, 2025, at 14:00, @ReduzziCarol will take the stage at FOCUS on TOP in the #LiquidBiopsy Session, exploring the role of circulating tumor cells (#CTCs) in #MRD monitoring with #ctDNA. Program and registration: 👇 ecm.meetingsrl.eu/focus_TOP25/de…

CDK4/6 inhibitors: mechanisms of resistance and where to find them. An outside of the box review Main takeaways: 🛑RB1 loss in #ctDNA predicts poorer PFS ⚠️CCNE1 gain impacts PALOMA-3 outcomes 🧩Role of ESR1 still unclear Read more👇 sciencedirect.com/science/articl… #bcsm #BreastCancer

With the growing efficacy of new antiHER2 agents, biomarker-driven de-escalation will become increasingly crucial for #PrecisionMedicine in #BreastCancer #bcsm @lindacucciniel1 @BlondeauxEva

Intriguing data presented by @lfoffano97 at the #SABCS24 poster session on how #ctDNA can be leveraged to enhance disease monitoring in metastatic #BreastCancer. Paving the way to a new #liquidbiopsy informed RECIST @CtcLaboratory #PrecisionMedicine #bcsm

Our @LGerratana shows the perspectives of adjuvant treatment de-escalation at the #AIOM24 #breastcancer educational session. #liquidbiopsy will play a crucial role in transitioning from prognostication to actual monitoring. #ctDNA #PrecisionMedicine @uniud @CroAviano

🔬 #ASCO2024 Insight: Dr @LGerratana discusses the genomic profiling of PR-negative and ER-low breast cancer subtypes. ER-low tumours show a mutational profile similar to triple-negative breast cancer, suggesting benefits from immunotherapy.

#ctDNA is gaining importance in #breastcancer. But what are its real clinical prospects? Excited to share our perspective: 'Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer?' 👉 doi.org/10.1080/147371…

Is ER low metastatic #BreastCancer a TNBC-like disease subtype? Check our circulating tumor DNA analysis 📍Poster Bd # 17 - Hall A, Metastatic Breast Cancer session ⏱️ 9:00 AM - 12:00 PM #ASCO24 #ctDNA #bcsm #liquidbiopsy

Say hello to OLGA, @CroAviano persOnaLized oncoloGy cAre flow platform It’s time to move from the paradigm of #PrecisionMedicine in #Oncology to a broader concept of #Personalized #Care, where treatments and monitoring strategies are holistically tailored around every person.

Great opportunity to get in touch with the International Society of Liquid Biopsy (ISLB @isliquidbiopsy) at booth 10027! #ASCO24 #LiquidBiopsy

Join Francois-Clement Bidard at the 20th Anniversary of Circulating Tumor Cells in Granada, Spain from May 24-25, 2024. Francois-Clement Bidard, MD PhD, is a Professor of Medical Oncology at Institut Curie & Versailles University, and also the vice-chair or the French breast cancer research group UCBG/Unicancer. For more information, please contact welcome@islb.info. #CTC20thAnniversary #SpeakerSpotlight @MJOSESERRANO19 @MCristofanill

Be part of the 20th Anniversary of Circulating Tumor Cells, organized by ISLB! 📅 Save the date for May 24 - 25, 2024, and join us as we unveil the impact of Circulating Tumor Cells, exploring two decades of discovery and clinical advancements in solid tumors. Chairs: @MCristofanill @MJOSESERRANO19 Hosted at Centro Pfizer-University of Granada-Junta De Andalucia De Genomica E Investigación Oncologica, Granada, Spain. Don't miss this opportunity to be part of the future of cancer research and treatment! More information please write to welcome@islb.info

What is the role of synonymous mutations (SYN) and variants of unknown significance (VUS) detected though #ctDNA next generation sequencing? Some interesting insights presented by @Elisabetta_mol at the #SABCS23 poster session #LiquidBiopsy #MBC

Check our companion posters on genetic and epigenetic #ctDNA profiling according to PR status in metastatic #breastcancer. 🔴during 1st line ET 🔼 ESR1 promoter methylation in PRpos 🔴after 1st line: 🔼ESR1 mut in PRpos #MBC 🔼GATA3 mut in PRneg #MBC #SABCS23 #liquidbiopsy

Moving from prognostication to pattern of progression at the #ESMO23 poster session with @lindacucciniel1 . Hazard distribution has different patterns across clinical and #LiquidBiopsy subgroups: can we #personalize disease monitoring in metastatic #BreastCancer?

A recent prospective study delved into baseline pharmacological profiling in patients treated for metastatic #BreastCancer using #palbociclib 🧵3/5 linkinghub.elsevier.com/retrieve/pii/S… #MBC